RICHARD LEVINE, National Institutes of Health, Bethesda REFERENCE: N Engl J Med 2006; 355:992 In pregnant women circulating levels of the anti-angiogenic substances: soluble endoglin and soluble Flt-1
RICHARD LEVINE, National Institutes of Health, Bethesda
REFERENCE: N Engl J Med 2006; 355:992
In pregnant women circulating levels of the anti-angiogenic substances: soluble endoglin and soluble Flt-1 herald the onset of preeclampsia, according to a publication in the New England Journal of Medicine. Richard Levine told Peter Goodwin about his group’s findings from the Calcium for Preeclampsia Prevention Trial which give hope of designing molecularly targeted drugs to treat preeclampsia or of spotting the disease early.
[audio:https://www.audiomedica.com/podcasting/fertility/070108_richard_levine.mp3]